Gengraf

Prophylaxis against heart transplant rejection, Ocular Rosacea, Disease + 37 more
Treatment
25 FDA approvals
20 Active Studies for Gengraf

What is Gengraf

CyclosporineThe Generic name of this drug
Treatment SummaryCyclosporine is a medication used to prevent organ transplant rejection and treat inflammatory and autoimmune conditions. It is derived from a fungus called Beauveria nivea and was first manufactured by Sandoz in 1983. It is now available in various brands, such as Novartis, which was formerly known as Sandoz.
Sandimmuneis the brand name
image of different drug pills on a surface
Gengraf Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Sandimmune
Cyclosporine
1983
68

Approved as Treatment by the FDA

Cyclosporine, also known as Sandimmune, is approved by the FDA for 25 uses which include inadequate response to conventional therapy and Psoriasis .
inadequate response to conventional therapy
Helps manage inadequate response to conventional therapy
Psoriasis
Helps manage severe Psoriasis
severe, recalcitrant Plaque psoriasis
Helps manage severe, recalcitrant Plaque psoriasis
Heymann Nephritis
Helps manage Glomerulonephritis, Membranous
Therapeutic procedure
contraindication or intolerance to other therapy
Helps manage contraindication or intolerance to other therapy
Bone Marrow
Rheumatoid Arthritis
Used to treat Rheumatoid Arthritis in combination with Methotrexate
Chronic Graft Versus Host Disease
Prophylaxis against heart transplant rejection
Patients who do not adequately respond to methotrexate alone
Helps manage Patients who do not adequately respond to methotrexate alone
Glomerulosclerosis
Helps manage Glomerulosclerosis
Steroid Resistant Nephrotic Syndrome
Helps manage Steroid Resistant Nephrotic Syndrome
Focal Segmental Glomerulosclerosis (FSGS)
Helps manage Focal Segmental Glomerulosclerosis (FSGS)
Nephrotic Syndrome
Helps manage Steroid Dependent Nephrotic Syndrome
Prophylaxis against graft versus host disease
Not responsive to other therapy
Helps manage Not responsive to other therapy
Therapeutic immunosuppression
Bone Marrow Transplantation
Liver
Prophylaxis against stem cell transplant rejection
Kidney Transplantation
Used to treat prophylaxis of renal transplant rejection in combination with Azathioprine
Nephrotic Syndrome
Helps manage Nephrotic Syndrome
Rheumatoid Arthritis
Helps manage severe, active Rheumatoid arthritis
Transplantation

Effectiveness

How Gengraf Affects PatientsCyclosporine is a drug used to suppress the activity of the immune system, helping to prolong the success of organ and bone marrow transplants. It also helps to prevent and control serious immune-related reactions, such as allograft rejection, graft versus host disease, and autoimmune disease. However, it can cause certain side effects, such as excessive hair growth, gum enlargement, increased cholesterol levels, and in some cases, kidney damage.
How Gengraf works in the bodyCyclosporine is a drug that stops inflammation by blocking the activation of T cells. It does this by binding to a receptor inside cells and forming a complex. This complex then prevents calcineurin from activating a certain factor, called NF-AT, which triggers the production of inflammatory chemicals like cytokines. By stopping this process, cyclosporine can reduce inflammation and stop T cell activation or growth. It also lowers levels of other substances associated with T cell function and thymocyte development.

When to interrupt dosage

The suggested dosage of Gengraf is contingent upon the diagnosed condition, such as Interstitial Cystitis, Focal Segmental Glomerulosclerosis (FSGS) and Excessive tearing. The measure of dosage is dependent on the mode of administration (e.g. Liquid - Intravenous or Ophthalmic; Topical) listed in the table below.
Condition
Dosage
Administration
severe, recalcitrant Plaque psoriasis
50.0 mg, 100.0 mg/mL, , 0.0009 mg/mL, 0.9 mg/mL, 0.1 %, 0.5 mg/mL, 0.09 %, 25.0 mg, 50.0 mg/mL, 100.0 mg, 10.0 mg, 0.05 %, 1.0 mg/mL, 2.5 mg/mL, 0.005 mg/mL
Liquid - Intravenous, Ophthalmic; Topical, Capsule, Solution / drops, Solution / drops - Ophthalmic; Topical, Capsule - Oral, Solution - Ophthalmic, Injection, solution - Intravenous, Oral, , Capsule, liquid filled - Oral, Intravenous, Emulsion - Ophthalmic, Injection, solution, Emulsion, Solution - Intravenous, Ophthalmic, Liquid, Solution, Emulsion - Ophthalmic; Topical, Capsule, liquid filled, Injection, Liquid - Topical, Injection - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Solution - Oral, Topical, Liquid - Ophthalmic, Liquid - Oral
Idiopathic Thrombocytopenic Purpura
50.0 mg, 100.0 mg/mL, , 0.0009 mg/mL, 0.9 mg/mL, 0.1 %, 0.5 mg/mL, 0.09 %, 25.0 mg, 50.0 mg/mL, 100.0 mg, 10.0 mg, 0.05 %, 1.0 mg/mL, 2.5 mg/mL, 0.005 mg/mL
Liquid - Intravenous, Ophthalmic; Topical, Capsule, Solution / drops, Solution / drops - Ophthalmic; Topical, Capsule - Oral, Solution - Ophthalmic, Injection, solution - Intravenous, Oral, , Capsule, liquid filled - Oral, Intravenous, Emulsion - Ophthalmic, Injection, solution, Emulsion, Solution - Intravenous, Ophthalmic, Liquid, Solution, Emulsion - Ophthalmic; Topical, Capsule, liquid filled, Injection, Liquid - Topical, Injection - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Solution - Oral, Topical, Liquid - Ophthalmic, Liquid - Oral
Glomerulosclerosis
50.0 mg, 100.0 mg/mL, , 0.0009 mg/mL, 0.9 mg/mL, 0.1 %, 0.5 mg/mL, 0.09 %, 25.0 mg, 50.0 mg/mL, 100.0 mg, 10.0 mg, 0.05 %, 1.0 mg/mL, 2.5 mg/mL, 0.005 mg/mL
Liquid - Intravenous, Ophthalmic; Topical, Capsule, Solution / drops, Solution / drops - Ophthalmic; Topical, Capsule - Oral, Solution - Ophthalmic, Injection, solution - Intravenous, Oral, , Capsule, liquid filled - Oral, Intravenous, Emulsion - Ophthalmic, Injection, solution, Emulsion, Solution - Intravenous, Ophthalmic, Liquid, Solution, Emulsion - Ophthalmic; Topical, Capsule, liquid filled, Injection, Liquid - Topical, Injection - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Solution - Oral, Topical, Liquid - Ophthalmic, Liquid - Oral
Kidney Transplantation
50.0 mg, 100.0 mg/mL, , 0.0009 mg/mL, 0.9 mg/mL, 0.1 %, 0.5 mg/mL, 0.09 %, 25.0 mg, 50.0 mg/mL, 100.0 mg, 10.0 mg, 0.05 %, 1.0 mg/mL, 2.5 mg/mL, 0.005 mg/mL
Liquid - Intravenous, Ophthalmic; Topical, Capsule, Solution / drops, Solution / drops - Ophthalmic; Topical, Capsule - Oral, Solution - Ophthalmic, Injection, solution - Intravenous, Oral, , Capsule, liquid filled - Oral, Intravenous, Emulsion - Ophthalmic, Injection, solution, Emulsion, Solution - Intravenous, Ophthalmic, Liquid, Solution, Emulsion - Ophthalmic; Topical, Capsule, liquid filled, Injection, Liquid - Topical, Injection - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Solution - Oral, Topical, Liquid - Ophthalmic, Liquid - Oral
Ulcerative Colitis
50.0 mg, 100.0 mg/mL, , 0.0009 mg/mL, 0.9 mg/mL, 0.1 %, 0.5 mg/mL, 0.09 %, 25.0 mg, 50.0 mg/mL, 100.0 mg, 10.0 mg, 0.05 %, 1.0 mg/mL, 2.5 mg/mL, 0.005 mg/mL
Liquid - Intravenous, Ophthalmic; Topical, Capsule, Solution / drops, Solution / drops - Ophthalmic; Topical, Capsule - Oral, Solution - Ophthalmic, Injection, solution - Intravenous, Oral, , Capsule, liquid filled - Oral, Intravenous, Emulsion - Ophthalmic, Injection, solution, Emulsion, Solution - Intravenous, Ophthalmic, Liquid, Solution, Emulsion - Ophthalmic; Topical, Capsule, liquid filled, Injection, Liquid - Topical, Injection - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Solution - Oral, Topical, Liquid - Ophthalmic, Liquid - Oral
Atopic Dermatitis
50.0 mg, 100.0 mg/mL, , 0.0009 mg/mL, 0.9 mg/mL, 0.1 %, 0.5 mg/mL, 0.09 %, 25.0 mg, 50.0 mg/mL, 100.0 mg, 10.0 mg, 0.05 %, 1.0 mg/mL, 2.5 mg/mL, 0.005 mg/mL
Liquid - Intravenous, Ophthalmic; Topical, Capsule, Solution / drops, Solution / drops - Ophthalmic; Topical, Capsule - Oral, Solution - Ophthalmic, Injection, solution - Intravenous, Oral, , Capsule, liquid filled - Oral, Intravenous, Emulsion - Ophthalmic, Injection, solution, Emulsion, Solution - Intravenous, Ophthalmic, Liquid, Solution, Emulsion - Ophthalmic; Topical, Capsule, liquid filled, Injection, Liquid - Topical, Injection - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Solution - Oral, Topical, Liquid - Ophthalmic, Liquid - Oral
Prophylaxis against stem cell transplant rejection
50.0 mg, 100.0 mg/mL, , 0.0009 mg/mL, 0.9 mg/mL, 0.1 %, 0.5 mg/mL, 0.09 %, 25.0 mg, 50.0 mg/mL, 100.0 mg, 10.0 mg, 0.05 %, 1.0 mg/mL, 2.5 mg/mL, 0.005 mg/mL
Liquid - Intravenous, Ophthalmic; Topical, Capsule, Solution / drops, Solution / drops - Ophthalmic; Topical, Capsule - Oral, Solution - Ophthalmic, Injection, solution - Intravenous, Oral, , Capsule, liquid filled - Oral, Intravenous, Emulsion - Ophthalmic, Injection, solution, Emulsion, Solution - Intravenous, Ophthalmic, Liquid, Solution, Emulsion - Ophthalmic; Topical, Capsule, liquid filled, Injection, Liquid - Topical, Injection - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Solution - Oral, Topical, Liquid - Ophthalmic, Liquid - Oral
Bulla
50.0 mg, 100.0 mg/mL, , 0.0009 mg/mL, 0.9 mg/mL, 0.1 %, 0.5 mg/mL, 0.09 %, 25.0 mg, 50.0 mg/mL, 100.0 mg, 10.0 mg, 0.05 %, 1.0 mg/mL, 2.5 mg/mL, 0.005 mg/mL
Liquid - Intravenous, Ophthalmic; Topical, Capsule, Solution / drops, Solution / drops - Ophthalmic; Topical, Capsule - Oral, Solution - Ophthalmic, Injection, solution - Intravenous, Oral, , Capsule, liquid filled - Oral, Intravenous, Emulsion - Ophthalmic, Injection, solution, Emulsion, Solution - Intravenous, Ophthalmic, Liquid, Solution, Emulsion - Ophthalmic; Topical, Capsule, liquid filled, Injection, Liquid - Topical, Injection - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Solution - Oral, Topical, Liquid - Ophthalmic, Liquid - Oral
Juvenile arthritis
50.0 mg, 100.0 mg/mL, , 0.0009 mg/mL, 0.9 mg/mL, 0.1 %, 0.5 mg/mL, 0.09 %, 25.0 mg, 50.0 mg/mL, 100.0 mg, 10.0 mg, 0.05 %, 1.0 mg/mL, 2.5 mg/mL, 0.005 mg/mL
Liquid - Intravenous, Ophthalmic; Topical, Capsule, Solution / drops, Solution / drops - Ophthalmic; Topical, Capsule - Oral, Solution - Ophthalmic, Injection, solution - Intravenous, Oral, , Capsule, liquid filled - Oral, Intravenous, Emulsion - Ophthalmic, Injection, solution, Emulsion, Solution - Intravenous, Ophthalmic, Liquid, Solution, Emulsion - Ophthalmic; Topical, Capsule, liquid filled, Injection, Liquid - Topical, Injection - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Solution - Oral, Topical, Liquid - Ophthalmic, Liquid - Oral
Excessive tearing
50.0 mg, 100.0 mg/mL, , 0.0009 mg/mL, 0.9 mg/mL, 0.1 %, 0.5 mg/mL, 0.09 %, 25.0 mg, 50.0 mg/mL, 100.0 mg, 10.0 mg, 0.05 %, 1.0 mg/mL, 2.5 mg/mL, 0.005 mg/mL
Liquid - Intravenous, Ophthalmic; Topical, Capsule, Solution / drops, Solution / drops - Ophthalmic; Topical, Capsule - Oral, Solution - Ophthalmic, Injection, solution - Intravenous, Oral, , Capsule, liquid filled - Oral, Intravenous, Emulsion - Ophthalmic, Injection, solution, Emulsion, Solution - Intravenous, Ophthalmic, Liquid, Solution, Emulsion - Ophthalmic; Topical, Capsule, liquid filled, Injection, Liquid - Topical, Injection - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Solution - Oral, Topical, Liquid - Ophthalmic, Liquid - Oral
Kidney Diseases
50.0 mg, 100.0 mg/mL, , 0.0009 mg/mL, 0.9 mg/mL, 0.1 %, 0.5 mg/mL, 0.09 %, 25.0 mg, 50.0 mg/mL, 100.0 mg, 10.0 mg, 0.05 %, 1.0 mg/mL, 2.5 mg/mL, 0.005 mg/mL
Liquid - Intravenous, Ophthalmic; Topical, Capsule, Solution / drops, Solution / drops - Ophthalmic; Topical, Capsule - Oral, Solution - Ophthalmic, Injection, solution - Intravenous, Oral, , Capsule, liquid filled - Oral, Intravenous, Emulsion - Ophthalmic, Injection, solution, Emulsion, Solution - Intravenous, Ophthalmic, Liquid, Solution, Emulsion - Ophthalmic; Topical, Capsule, liquid filled, Injection, Liquid - Topical, Injection - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Solution - Oral, Topical, Liquid - Ophthalmic, Liquid - Oral
Chronic Graft Versus Host Disease
50.0 mg, 100.0 mg/mL, , 0.0009 mg/mL, 0.9 mg/mL, 0.1 %, 0.5 mg/mL, 0.09 %, 25.0 mg, 50.0 mg/mL, 100.0 mg, 10.0 mg, 0.05 %, 1.0 mg/mL, 2.5 mg/mL, 0.005 mg/mL
Liquid - Intravenous, Ophthalmic; Topical, Capsule, Solution / drops, Solution / drops - Ophthalmic; Topical, Capsule - Oral, Solution - Ophthalmic, Injection, solution - Intravenous, Oral, , Capsule, liquid filled - Oral, Intravenous, Emulsion - Ophthalmic, Injection, solution, Emulsion, Solution - Intravenous, Ophthalmic, Liquid, Solution, Emulsion - Ophthalmic; Topical, Capsule, liquid filled, Injection, Liquid - Topical, Injection - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Solution - Oral, Topical, Liquid - Ophthalmic, Liquid - Oral
Disease
50.0 mg, 100.0 mg/mL, , 0.0009 mg/mL, 0.9 mg/mL, 0.1 %, 0.5 mg/mL, 0.09 %, 25.0 mg, 50.0 mg/mL, 100.0 mg, 10.0 mg, 0.05 %, 1.0 mg/mL, 2.5 mg/mL, 0.005 mg/mL
Liquid - Intravenous, Ophthalmic; Topical, Capsule, Solution / drops, Solution / drops - Ophthalmic; Topical, Capsule - Oral, Solution - Ophthalmic, Injection, solution - Intravenous, Oral, , Capsule, liquid filled - Oral, Intravenous, Emulsion - Ophthalmic, Injection, solution, Emulsion, Solution - Intravenous, Ophthalmic, Liquid, Solution, Emulsion - Ophthalmic; Topical, Capsule, liquid filled, Injection, Liquid - Topical, Injection - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Solution - Oral, Topical, Liquid - Ophthalmic, Liquid - Oral
Dry Eye Syndromes
50.0 mg, 100.0 mg/mL, , 0.0009 mg/mL, 0.9 mg/mL, 0.1 %, 0.5 mg/mL, 0.09 %, 25.0 mg, 50.0 mg/mL, 100.0 mg, 10.0 mg, 0.05 %, 1.0 mg/mL, 2.5 mg/mL, 0.005 mg/mL
Liquid - Intravenous, Ophthalmic; Topical, Capsule, Solution / drops, Solution / drops - Ophthalmic; Topical, Capsule - Oral, Solution - Ophthalmic, Injection, solution - Intravenous, Oral, , Capsule, liquid filled - Oral, Intravenous, Emulsion - Ophthalmic, Injection, solution, Emulsion, Solution - Intravenous, Ophthalmic, Liquid, Solution, Emulsion - Ophthalmic; Topical, Capsule, liquid filled, Injection, Liquid - Topical, Injection - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Solution - Oral, Topical, Liquid - Ophthalmic, Liquid - Oral
Interstitial Cystitis
50.0 mg, 100.0 mg/mL, , 0.0009 mg/mL, 0.9 mg/mL, 0.1 %, 0.5 mg/mL, 0.09 %, 25.0 mg, 50.0 mg/mL, 100.0 mg, 10.0 mg, 0.05 %, 1.0 mg/mL, 2.5 mg/mL, 0.005 mg/mL
Liquid - Intravenous, Ophthalmic; Topical, Capsule, Solution / drops, Solution / drops - Ophthalmic; Topical, Capsule - Oral, Solution - Ophthalmic, Injection, solution - Intravenous, Oral, , Capsule, liquid filled - Oral, Intravenous, Emulsion - Ophthalmic, Injection, solution, Emulsion, Solution - Intravenous, Ophthalmic, Liquid, Solution, Emulsion - Ophthalmic; Topical, Capsule, liquid filled, Injection, Liquid - Topical, Injection - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Solution - Oral, Topical, Liquid - Ophthalmic, Liquid - Oral
Bone Marrow Transplantation
50.0 mg, 100.0 mg/mL, , 0.0009 mg/mL, 0.9 mg/mL, 0.1 %, 0.5 mg/mL, 0.09 %, 25.0 mg, 50.0 mg/mL, 100.0 mg, 10.0 mg, 0.05 %, 1.0 mg/mL, 2.5 mg/mL, 0.005 mg/mL
Liquid - Intravenous, Ophthalmic; Topical, Capsule, Solution / drops, Solution / drops - Ophthalmic; Topical, Capsule - Oral, Solution - Ophthalmic, Injection, solution - Intravenous, Oral, , Capsule, liquid filled - Oral, Intravenous, Emulsion - Ophthalmic, Injection, solution, Emulsion, Solution - Intravenous, Ophthalmic, Liquid, Solution, Emulsion - Ophthalmic; Topical, Capsule, liquid filled, Injection, Liquid - Topical, Injection - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Solution - Oral, Topical, Liquid - Ophthalmic, Liquid - Oral
Liver
50.0 mg, 100.0 mg/mL, , 0.0009 mg/mL, 0.9 mg/mL, 0.1 %, 0.5 mg/mL, 0.09 %, 25.0 mg, 50.0 mg/mL, 100.0 mg, 10.0 mg, 0.05 %, 1.0 mg/mL, 2.5 mg/mL, 0.005 mg/mL
Liquid - Intravenous, Ophthalmic; Topical, Capsule, Solution / drops, Solution / drops - Ophthalmic; Topical, Capsule - Oral, Solution - Ophthalmic, Injection, solution - Intravenous, Oral, , Capsule, liquid filled - Oral, Intravenous, Emulsion - Ophthalmic, Injection, solution, Emulsion, Solution - Intravenous, Ophthalmic, Liquid, Solution, Emulsion - Ophthalmic; Topical, Capsule, liquid filled, Injection, Liquid - Topical, Injection - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Solution - Oral, Topical, Liquid - Ophthalmic, Liquid - Oral
Rejection; Transplant, Kidney
50.0 mg, 100.0 mg/mL, , 0.0009 mg/mL, 0.9 mg/mL, 0.1 %, 0.5 mg/mL, 0.09 %, 25.0 mg, 50.0 mg/mL, 100.0 mg, 10.0 mg, 0.05 %, 1.0 mg/mL, 2.5 mg/mL, 0.005 mg/mL
Liquid - Intravenous, Ophthalmic; Topical, Capsule, Solution / drops, Solution / drops - Ophthalmic; Topical, Capsule - Oral, Solution - Ophthalmic, Injection, solution - Intravenous, Oral, , Capsule, liquid filled - Oral, Intravenous, Emulsion - Ophthalmic, Injection, solution, Emulsion, Solution - Intravenous, Ophthalmic, Liquid, Solution, Emulsion - Ophthalmic; Topical, Capsule, liquid filled, Injection, Liquid - Topical, Injection - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Solution - Oral, Topical, Liquid - Ophthalmic, Liquid - Oral
non-immunocompromised
50.0 mg, 100.0 mg/mL, , 0.0009 mg/mL, 0.9 mg/mL, 0.1 %, 0.5 mg/mL, 0.09 %, 25.0 mg, 50.0 mg/mL, 100.0 mg, 10.0 mg, 0.05 %, 1.0 mg/mL, 2.5 mg/mL, 0.005 mg/mL
Liquid - Intravenous, Ophthalmic; Topical, Capsule, Solution / drops, Solution / drops - Ophthalmic; Topical, Capsule - Oral, Solution - Ophthalmic, Injection, solution - Intravenous, Oral, , Capsule, liquid filled - Oral, Intravenous, Emulsion - Ophthalmic, Injection, solution, Emulsion, Solution - Intravenous, Ophthalmic, Liquid, Solution, Emulsion - Ophthalmic; Topical, Capsule, liquid filled, Injection, Liquid - Topical, Injection - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Solution - Oral, Topical, Liquid - Ophthalmic, Liquid - Oral
Transplantation
50.0 mg, 100.0 mg/mL, , 0.0009 mg/mL, 0.9 mg/mL, 0.1 %, 0.5 mg/mL, 0.09 %, 25.0 mg, 50.0 mg/mL, 100.0 mg, 10.0 mg, 0.05 %, 1.0 mg/mL, 2.5 mg/mL, 0.005 mg/mL
Liquid - Intravenous, Ophthalmic; Topical, Capsule, Solution / drops, Solution / drops - Ophthalmic; Topical, Capsule - Oral, Solution - Ophthalmic, Injection, solution - Intravenous, Oral, , Capsule, liquid filled - Oral, Intravenous, Emulsion - Ophthalmic, Injection, solution, Emulsion, Solution - Intravenous, Ophthalmic, Liquid, Solution, Emulsion - Ophthalmic; Topical, Capsule, liquid filled, Injection, Liquid - Topical, Injection - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Solution - Oral, Topical, Liquid - Ophthalmic, Liquid - Oral

Warnings

Gengraf has six contraindications. It should not be taken simultaneously with any of the conditions noted in the following table.Gengraf Contraindications
Condition
Risk Level
Notes
Ocular neoplasms malignancy unspecified
Do Not Combine
Rheumatoid Arthritis
Do Not Combine
Toxoplasma Infections
Do Not Combine
Toxoplasma Infections
Do Not Combine
Hypertensive disease
Do Not Combine
Abnormal Renal Function
Do Not Combine
Psoriasis
Do Not Combine
active periocular infections
Do Not Combine
Rheumatoid Arthritis
Do Not Combine
Rheumatoid Arthritis
Do Not Combine
active ocular infections
Do Not Combine
Pulse Frequency
Do Not Combine
Infection
Do Not Combine
Rheumatoid Arthritis
Do Not Combine
Secondary Immunodeficiencies (SID)
Do Not Combine
Rheumatoid Arthritis
Do Not Combine
Hypertensive disease
Do Not Combine
Rheumatoid Arthritis
Do Not Combine
Rheumatoid Arthritis
Do Not Combine
Radiation Therapy
Do Not Combine
Abnormal Renal Function
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Cyclosporine may interact with Toxoplasma Infections
There are 20 known major drug interactions with Gengraf.
Common Gengraf Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The serum concentration of Abemaciclib can be increased when it is combined with Cyclosporine.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be decreased when combined with Cyclosporine.
Alectinib
Major
The metabolism of Alectinib can be decreased when combined with Cyclosporine.
Aliskiren
Major
The serum concentration of Aliskiren can be increased when it is combined with Cyclosporine.
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Cyclosporine.
Gengraf Toxicity & Overdose RiskThe lowest toxic dose of cyclosporine in rats is 1480 mg/kg and the toxicity level for humans is 12 mg/kg. Symptoms of an overdose include nausea, flushing, trembling, dizziness, vomiting, and loss of appetite. These symptoms usually go away within a day, but the feeling of increased body girth may take up to two weeks to resolve. Treatment for cyclosporine overdose should include forced vomiting and stomach pumping within two hours of ingestion, as dialysis and charcoal hemoperfusion are not effective methods of removing the drug from the body.
image of a doctor in a lab doing drug, clinical research

Gengraf Novel Uses: Which Conditions Have a Clinical Trial Featuring Gengraf?

81 clinical trials are being conducted to investigate the potential of Gengraf to alleviate Chronic Graft Versus Host Disease, Kidney Diseases and Ulcerative Colitis.
Condition
Clinical Trials
Trial Phases
Chronic Graft Versus Host Disease
32 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 4, Phase 3, Early Phase 1
Atopic Dermatitis
75 Actively Recruiting
Phase 3, Phase 4, Not Applicable, Phase 1, Phase 2, Early Phase 1
Lupus Nephritis
20 Actively Recruiting
Phase 4, Phase 2, Phase 1, Phase 3
Dry Eye Syndromes
1 Actively Recruiting
Phase 3
Nephrotic Syndrome
0 Actively Recruiting
non-immunocompromised
0 Actively Recruiting
Transplantation
0 Actively Recruiting
Interstitial Cystitis
16 Actively Recruiting
Phase 2, Early Phase 1, Not Applicable, Phase 1, Phase 3
Kidney Diseases
0 Actively Recruiting
Ulcerative Colitis
0 Actively Recruiting
Excessive tearing
0 Actively Recruiting
Bulla
0 Actively Recruiting
Heart
2 Actively Recruiting
Phase 2, Not Applicable
Rejection; Transplant, Kidney
10 Actively Recruiting
Phase 3, Phase 1, Phase 2, Phase 4, Not Applicable, Early Phase 1
Rejection, Transplant
2 Actively Recruiting
Phase 2
severe, recalcitrant Plaque psoriasis
0 Actively Recruiting
Patients who do not adequately respond to methotrexate alone
0 Actively Recruiting
Rheumatoid Arthritis
0 Actively Recruiting
Rejection; Transplant, Liver
0 Actively Recruiting
Therapeutic immunosuppression
0 Actively Recruiting

Gengraf Reviews: What are patients saying about Gengraf?

5Patient Review
11/19/2008
Gengraf for Prevent Kidney Transplant Rejection
I received a kidney transplant in 1999 and, overall, I think it was successful.
5Patient Review
1/22/2009
Gengraf for Treatment to Prevent Reaction After Bone Marrow Transplant
I've been using this medication for less than a year and it's doing a great job. I never had any difficulty with nausea, and my kidneys are tested regularly and doing fine so far.
5Patient Review
1/23/2008
Gengraf for Prevention of Liver Transplant Rejection
I have been on Genfraf for 5 years and was wondering what could cause my level to drop low when I take 2 doses BID? I would like to know how long it takes gengraf to get through my system, and how long I would take it after vomiting?
5Patient Review
7/15/2009
Gengraf for Prevention of Liver Transplant Rejection
I received a liver transplant in December 2002 and was prescribed this medication 2-3 months afterwards. I have had no side effects or rejections, and it has kept me healthy overall. The only downside is that it is quite expensive; however, the capsules are easy to take. I believe it raised my blood pressure slightly, but I take Norvasc 5mg once daily to counteract that. All of my blood work has been normal thus far while taking this drug.
3.7Patient Review
10/24/2012
Gengraf for Prevent Kidney Transplant Rejection
After losing my insurance, I had to switch from Neoral to Gengraf. I feel like Gengraf doesn't work as well for me; I'm constantly in pain and I don't know if it's the medication or not.
2.7Patient Review
2/24/2012
Gengraf for Prevent Kidney Transplant Rejection
I switched to Gengraf from another Cyclosporine modulator a few months ago, and I've developed mouth and throat sores. Is this a common side effect?
1Patient Review
11/30/2009
Gengraf for Prevent Kidney Transplant Rejection
I do not take this medication, but I know someone who does. They've been taking it for at least three years, even though it's expired. I'm wondering if there are any health risks associated with taking expired medication. Can anyone provide some insight?

Patient Q&A Section about gengraf

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the difference between Neoral and GENGRAF?

"Gengraf is equivalent to Neoral in terms of efficacy. Additionally, Gengraf is well tolerated and can be used interchangeably with Neoral in stable Chinese renal allograft recipients."

Answered by AI

Is GENGRAF an immunosuppressant?

"GENGRAF is a drug that suppresses the immune system, making the body more susceptible to infection and disease. When taken with other immunosuppressant drugs, the effects are amplified."

Answered by AI

Is GENGRAF brand or generic?

"Gengraf is an immunosuppressant drug used to prevent organ rejection in people who have undergone kidney, liver, or heart transplant surgery. It is also sometimes used to treat severe cases of psoriasis or rheumatoid arthritis. A generic form of Gengraf is also available."

Answered by AI

What is GENGRAF used for?

"Cyclosporine capsules and oral solution are prescription medicines used to help prevent organ rejection in people who have received a kidney, liver, or heart transplant."

Answered by AI

Clinical Trials for Gengraf

Have you considered Gengraf clinical trials? We made a collection of clinical trials featuring Gengraf, we think they might fit your search criteria.
Have you considered Gengraf clinical trials? We made a collection of clinical trials featuring Gengraf, we think they might fit your search criteria.
Have you considered Gengraf clinical trials? We made a collection of clinical trials featuring Gengraf, we think they might fit your search criteria.